Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

The labelling puts it in direct contention with Pfizer's blockbuster Vyndamax/Vyndaqel/Vynmac franchise – based on tafamidis – which has been approved for ATTR-CM since 2019 and is also used ...

BridgeBio Pharma's robust pipeline, favorable policy shifts, and milestone payments position it for substantial future growth ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other safe dividend stocks. Dividend-paying stocks have long held a special place among investors ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other Jeff Smith’s top activist targets. Jeff Smith is arguably the “most feared man” in corporate ...

Pfizer PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q1 2025 earnings on April 29.

Video content above is prompted by the following: The NLA’s 2024 recommendation comes as a “focused update” to its 2019 scientific statement on the use of Lp(a) in clinical practice.

Morphological changes in the vasculature due to amyloid deposits may contribute to vascular dysfunction and contribute to the impaired cardiovascular profile observed in patients with ...